Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28721129 | 0.85 | — | — | |
| SCHEMBL5040132 | 0.73 | PIK3CD (0.34) | — | |
| SCHEMBL5035540 | 0.73 | LSS (0.33) | — | |
| SCHEMBL20590333 | 0.71 | DNM1 (0.44) | — | |
| SCHEMBL4446107 | 0.71 | — | — | |
| SCHEMBL29560170 | 0.70 | ALDH1A1 (0.30) | — | |
| SCHEMBL5035693 | 0.70 | — | — | |
| SCHEMBL16345829 | 0.69 | — | — | |
| SCHEMBL8144963 | 0.67 | MAPT (0.43) | MAPT | |
| SCHEMBL10607367 | 0.65 | MAPT (0.41) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117320706-A | Aminothiol ester compounds or derivatives thereof as immunomodulators | 高级生物设计公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4284360-A1 | AMINOTHIOLESTER COMPOUND OR DERIVATIVE THEREOF FOR USE AS AN IMMUNOMODULATORY AGENT | Advanced Biodesign (FR) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022162196-A1 | AMINOTHIOLESTER COMPOUND OR DERIVATIVE THEREOF FOR USE AS AN IMMUNOMODULATORY AGENT | ADVANCED BIODESIGN (FR) | 2022-08-04 | — | — | WO | disclosed |
| CN-114341110-A | Aminothiol ester compound and use thereof | 高级生物设计公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021019071-A1 | AMINOTHIOLESTER COMPOUNDS AND USES THEREOF | ADVANCED BIODESIGN (FR) | 2021-02-04 | — | — | WO | disclosed |
| EP-1349833-B1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | disclosed |
| CN-1245385-C | indole and indoline derivatives | HOFFMANN LA ROCHE (CH) | 2006-03-15 | — | — | CN | disclosed |
| CN-1733723-A | Indole and dihydroindole derivatives | HOFFMANN LA ROCHE (CH) | 2006-02-15 | — | — | CN | disclosed |
| CN-1476432-A | indole and indoline derivatives | - | 2004-02-18 | — | — | CN | disclosed |
| EP-1349833-A1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6503907-B2 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002044149-A1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | LSS, CYP51A1, DHCR7 | MAPT 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.